AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03645863
Drug: Iron supplement C
RxNorm normalized name: HERBAL IRON SUPPLEMENT CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT03645863
Drug: Iron supplement D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02535689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00727103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
Trial: NCT00676832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solid capsule dosage form administered orally once daily.
Trial: NCT01277211
Drug: ENG 120 µg + EE 15 µg intravaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
Trial: NCT01382888
Drug: Heparin 2,400 IU /ml Cutaneous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
Trial: NCT00240279
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02074007
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin ear drops (placebo) drops administered as needed for ear pain
Trial: NCT01627678
Drug: Vacc-C5/GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
Trial: NCT01627678
Drug: Vacc-C5/Alhydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
Trial: NCT03206346
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, capsules daily for 5 days.
Trial: NCT03899909
Drug: Placebo SAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension
Trial: NCT03899909
Drug: GLPG3121 MAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
Trial: NCT03899909
Drug: Placebo MAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension, daily for 13 days
Trial: NCT01160328
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5g - 1% testosterone gel, daily x 7 weeks
Trial: NCT04164290
Drug: Jiashen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet
Trial: NCT04164290
Drug: Jiashen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets
Trial: NCT04164290
Drug: Jiashen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets
Trial: NCT04164290
Drug: Jiashen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets
Trial: NCT04164290
Drug: Jiashen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets
Trial: NCT04164290
Drug: Jiashen Tablets Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet
Trial: NCT04164290
Drug: Jiashen Tablets Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets
Trial: NCT04164290
Drug: Jiashen Tablets Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets
Trial: NCT04164290
Drug: Jiashen Tablets Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets
Trial: NCT04164290
Drug: Jiashen Tablets Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets
Trial: NCT04164290
Drug: Jiashen Tablets Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 tablets
Trial: NCT02443740
Drug: BIIB118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
Trial: NCT02443740
Drug: BIIB118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
Trial: NCT00489255
Drug: Tigan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, 300mg three times daily
Trial: NCT00489255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, three times daily
Trial: NCT02982837
Drug: PEG-IFN & Nucleos(t)tide analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
Trial: NCT03008382
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Trial: NCT02742883
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT02546661
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
Trial: NCT02546661
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736
Trial: NCT02546661
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 (durvalumab) + AZD1775
Trial: NCT02546661
Drug: AZD9150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 (durvalumab) + AZD9150
Trial: NCT02537691
Drug: Oral Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids will be administered as per investigator discretion.
Trial: NCT02028676
Drug: Arm A: ABC+3TC+NNRTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Trial: NCT02028676
Drug: Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Trial: NCT02028676
Drug: Once-daily ABC+3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02028676
Drug: Twice-daily ABC+3TC
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01871766
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)
Trial: NCT01871766
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.
Trial: NCT01871766
Drug: ^1^1C-methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Trial: NCT02033031
Drug: Lucentis intravitreal injection
RxNorm normalized name: Lucentis Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucentis intravitreal injection
Trial: NCT00683657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 4 weeks
Trial: NCT00194779
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00194779
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00194779
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00194779
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03074630
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 9 weeks 10mg dapagliflozin once daily
Trial: NCT00852202
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules, oral administration, once daily dosing
Trial: NCT00508430
Drug: ASP8825
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00508430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04821778
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 Antibody
Trial: NCT02773602
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
Trial: NCT02051621
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
Trial: NCT04541134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
Trial: NCT00715429
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
Trial: NCT00504270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily
Trial: NCT00504270
Drug: RG3421 120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg po daily
Trial: NCT00504270
Drug: RG3421 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg po daily
Trial: NCT00261326
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg once daily
Trial: NCT00261326
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium tablets once daily
Trial: NCT02083627
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT03580473
Drug: SATURNO II association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opthalmic solution, 4 times a day
Trial: NCT03580473
Drug: Vigadexa®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opthalmic solution, 4 times a day
Trial: NCT03529201
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: painkiller during GA
Trial: NCT01042769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control po daily
Trial: NCT00828165
Drug: ARRY-300, MEK inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, escalating
Trial: NCT01527188
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 6 months
Trial: NCT01839110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth twice per day for a total of 26 weeks.
Trial: NCT03341390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Placebo administered twice daily
Trial: NCT02000453
Drug: GSK2586184 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
Trial: NCT03843229
Drug: Cinobufacini injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Trial: NCT03843229
Drug: cinobufacini tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Trial: NCT01183676
Drug: DEPAKOTE® Tablets, 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 500 mg Tablet, under fed conditions
Trial: NCT04313881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match magrolimab administered intravenously
Trial: NCT00496665
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
Trial: NCT00496665
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
Trial: NCT02243553
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00672074
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02147548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02457039
Drug: Cytoxan-containing chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\].
Trial: NCT01039701
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral, 3 times daily
Trial: NCT04663139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01039701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral, 3 times daily, 4 weeks
Trial: NCT01859481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
Trial: NCT00536003
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
Trial: NCT01022346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
Trial: NCT01022346
Drug: RO5217790
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
Trial: NCT01562938
Drug: MEDI-557
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-557 low-dose
Trial: NCT03595644
Drug: TKI
RxNorm normalized name: Catkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received EGFR-TKI treatment
Trial: NCT02937168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
Trial: NCT02639130
Drug: Exendin [9-39]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
Trial: NCT02639130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion as challenge agent
Trial: NCT01562938
Drug: MEDI-557
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-557 high-dose
Trial: NCT04659642
Drug: Fentanyl Citrate Injection
RxNorm normalized name: Fentanyl Citrate Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the drug is given 15 minutes before the estimated end of surgery
Trial: NCT02677116
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin administered IV.
Trial: NCT00729833
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-751,871 IV, every 3 weeks
Trial: NCT00979836
Drug: Calcium Dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/ three times/day for 6 months (capsules)
Trial: NCT00347386
Drug: Drug: Zinc (zinc sulphate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolvable tablet 10 mg. Once daily during the illness
Trial: NCT00347386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, once daily
Trial: NCT02457221
Drug: Cyclophosphamide injections
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection
Trial: NCT01737580
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via subcutaneous injection until week 24.
Trial: NCT02210104
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 administered intravenously 2 days prior to T cell infusion.
Trial: NCT02126826
Drug: Placebo to BI 1026706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Rising Doses (oral solution / tablet, identical to active treatment)
Trial: NCT03410056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a subcutaneous injection.
Trial: NCT00808314
Drug: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
Trial: NCT00853099
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01078870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1\~2#/cap QD
Trial: NCT00239174
Drug: SR147778
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00827918
Drug: MK-8998
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.